Aspirin increases ferritin synthesis in endothelial cells: A novel antioxidant pathway

Circulation Research

Volumn 82, Issue 9, 1998, Pages 1016-1020

  Oberle, Stefanie ^a   Polte, Tobias ^a   Abate, Aida ^a   Podhaisky, Hans Peter ^a   Schröder, Henning ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Antioxidant defense mechanism; Aspirin; Endothelial cell; Ferritin; Gene expression

Indexed keywords

ACETYLSALICYLIC ACID;

ANIMAL CELL; ARTICLE; ATHEROGENESIS; CELL PROTECTION; CELL VIABILITY; CONCENTRATION RESPONSE; ENDOTHELIUM CELL; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; HOUSEKEEPING GENE; IRON METABOLISM; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL;

EID: 0032543286     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.82.9.1016     Document Type: Article

References (38)

1. Fuster V, Dyken ML, Vokonas PS, Hennekens C. Aspirin as a therapeutic agent in cardiovascular disease. Circulation. 1993;87:659-675.
2. Samuelsson B, Granström E, Green K, Hamberg M, Hammarström S. Prostaglandins. Annu Rev Biochem. 1975;44:669-695.
3. Reilly IAG, FitzGerald GA. Aspirin in cardiovascular disease. Drugs. 1988;35:154-176.
4. Aruoma OI, Halliwell B. The iron-binding and hydroxyl radical scavenging action of anti-inflammatory drugs. Xenobiotica. 1988;18:459-470.
5. Woollard AC, Wolff SP, Bascal ZA. Antioxidant characteristics of some potential anticataract agents: studies of aspirin, paracetamol, and bendazac provide support for an oxidative component of cataract. Free Radic Biol Med. 1990;9:299-305.
6. Podhaisky HP, Abate A, Polte T, Oberle S, Schröder H. Aspirin protects endothelial cells from oxidative stress: possible synergism with vitamin E. FEBS Lett. 1997;417:349-351.
7. Balla G, Jacob HS, Balla J, Rosenberg M, Nath K, Apple F, Eaton JW, Vercellotti GM. Ferritin: a cytoprotective antioxidant strategem of endothelium. J Biol Chem. 1992;267:18148-18153.
8. Cairo G, Tacchini L, Pogliaghi G, Anzon E, Tomasi A, Bemelli-Zazzera A. Induction of ferritin synthesis by oxidative stress. J Biol Chem. 1995;270:700-703.
9. Juckelt MB, Balla J, Balla G, Jessurun J, Jacob HS, Vercellotti GM. Ferritin protects endothelial cells from oxidized low density lipoprotein in vitro. Am J Pathol. 1995;147:782-789.
10. Kim YM, Bergonia H, Lancaster JR. Nitrogen oxide-induced autoprotection in isolated rat hepatocytes. FEBS Lett. 1995;374:228-232.
11. Schröder H, Warren S, Bargetzi MJ, Torti SV, Torti FM. N-Acetyl-L-cysteine protects endothelial cells but not L929 tumor cells from tumor necrosis factor-α-mediated cytotoxicity. Naunyn Schmiedebergs Arch Pharmacol. 1993;347:664-666.
12. Akarasereenont P, Mitchell JA, Appelton I, Thiemermann C, Vane JR. Involvement of tyrosine kinase in the induction of cyclooxygenase and nitric oxide synthase by endotoxin in cultured cells. Br J Pharmacol. 1994;113:1522-1528.
13. Oberle S, Schröder H. Ferritin may mediate SIN-1-induced protection against oxidative stress. Nitric Oxide Biol Chem (Arch Biochem Biophys B). 1997;1:308-314.
14. Flick DA, Gifford GE. Comparison of in vitro cell cytotoxic assays for tumor necrosis factor. J Immunol Methods. 1984;68:167-175.
15. Polte T, Oberle S, Schröder H. The nitric oxide donor SIN-1 protects endothelial cells from tumor necrosis factor-α-mediated cytotoxicity: possible role for cyclic GMP and heme oxygenase. J Mol Cell Cardiol. 1997;29:3305-3310.
16. Wink DA, Cook JA, Pacelli R, DeGraff W, Gamson J, Liebmann J, Krishna MC, Mitchell JB. The effect of various nitric oxide-donor agents on hydrogen peroxide-mediated toxicity: a direct correlation between nitric oxide formation and protection. Arch Biochem Biophys. 1996;331:241-248.
17. Wai SN, Nakayama K, Umene K, Moriya T, Amako K. Construction of a ferritin-deficient mutant of Campylobacter jejuni: contribution of ferritin to iron storage and protection against oxidative stress. Mol Microbiol. 1996;20:1127-1134.
18. Patrono C. Aspirin and human platelets: from clinical trials to acetylation of cyclooxygenase and back. Trends Pharmacol Sci. 1989;10:453-458.
19. 2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med. 1991;325:1137-1141.
20. Kopp E, Ghosh S, Inhibition of NF-kappa B by sodium salicylate and aspirin. Science. 1994;265:956-959.
21. Weber C, Erl W, Pietsch A, Weber PC. Aspirin inhibits nuclear factor-kappa B mobilization and monocyte adhesion in stimulated human endothelial cells. Circulation. 1995;91:1914-1917.
22. Shackelford RE, Alford PB, Xue Y, Thai SF, Adams DO, Pizzo S. Aspirin inhibits tumor necrosis factor-alpha gene expression in murine tissue macrophages. Mol Pharmacol. 1997;52:421-429.
23. Amin AR, Vyas P, Attur M, Leszczynska-Piziak J, Patel IR, Weissmann G, Abramson SB. The mode of action of aspirin-like drugs: effect on inducible nitric oxide synthase. Proc Natl Acad Sci U S A. 1995;92:7926-7930.
24. Kwon G, Hill JR, Corbett JA, McDaniel ML. Effects of aspirin on nitric oxide formation and de novo protein synthesis by RINm5F cells and rat islets. Mol Pharmacol. 1997;52:398-405.
25. Harrison PM, Arosio P. The ferritins: molecular properties, iron storage function and cellular regulation. Biochim Biophys Acta. 1996;1275:161-203.
26. Schwarz KB, Arey BJ, Tolman K, Mahanty S. Iron chelation as a possible mechanism for aspirin-induced malondialdehyde production by mouse liver microsomes and mitochondria. J Clin Invest. 1988;81:165-170.
27. Salonen JT, Nyyssönen K, Korpela H, Tuomilehto J, Seppänen R, Salonen R. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation. 1992;86:803-811.
28. Sullivan JL. Stored iron and ischemic heart disease: empirical support for a new paradigm. Circulation. 1992;86:1036-1037.
29. Kiechl S, Aichner F, Gerstenbrand F, Egger G, Mair A, Rungger G, Spogler F, Jarosch E, Oberhollenzer F, Willeit J. Body iron stores and presence of carotid atherosclerosis: results from the Bruneck study. Arterioscler Thromb. 1994;14:1625-1630.
30. Tuomainen TP, Salonen R, Nyyssonen K, Salonen JT. Cohort study of relation between donating blood and risk of myocardial infarction in 2682 men in eastern Finland. BMJ. 1997;314:793-794.
31. Smith C, Mitchinson MJ, Aruoma OI, Halliwell B. Stimulation of lipid peroxidation and hydroxyl-radical generation by the contents of human atherosclerotic lesions. Biochem J. 1992;286:803-811.
32. Pang JHS, Jiang MJ, Chen YL, Wang FW, Wang DL, Chu SH, Chau LY. Increased ferritin gene expression in atherosclerotic lesions. J Clin Invest. 1996;97:2204-2212.
33. Crichton RR, Charloteaux-Wauters M. Iron transport and storage. Eur J Biochem. 1987;164:485-506.
34. Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medicine. Oxford, UK: Clarendon Press; 1989.
35. Brieland JK, Clarke SJ, Karmiol S, Phan SH, Fantone JC. Transferrin: a potential source of iron for oxygen free radical-mediated endothelial cell injury. Arch Biochem Biophys. 1992;294:265-270.
36. Kawasaki N, Tanimoto T, Tanaka A, Hayakawa T, Miyasaka N. Determination of non-protein-bound iron in human synovial fluid by high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Appl. 1994;656:436-440.
37. Paller MS, Hedlund BE. Role of iron in postischemic renal injury in the rat. Kidney Int. 1988;34:474-480.
38. Kadiiska MB, Burkitt MJ, Xiang QH, Mason RP. Iron supplementation generates hydroxyl radical in vivo: an ESR spin-trapping investigation. J Clin Invest. 1995;96:1653-1657.